Phase III Randomized Study of Radiotherapy in the Prevention of Metastatic
Skin Nodules Following Invasive Diagnostic Procedures in Patients With
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have
Diagnostic Procedures to Identify Malignant Mesothelioma
Basic Trial Information
Phase: Phase III
Type: Supportive care, Treatment
Age: Not specified
Protocol IDs: CRC-BOC-L52, EU-20033, NCT00006231
A total of 44 patients (22 per arm) will be accrued for this study
within 2 years.
This is a randomized study.
Patients are randomized to 1 of 2 treatment arms.
Quality of life is assessed at baseline, and then at 1, 2, 4, 6, 9,
and 12 months.
Patients are followed at 1, 2, 4, 6, 9, and 12 months.
The purpose of most clinical trials listed in this database is to test
new cancer treatments, or new methods of diagnosing, screening, or preventing
cancer. Because all potentially harmful side effects are not known before
a trial is conducted, dose and schedule modifications may be required
for participants if they develop side effects from the treatment or
test. The therapy or test described in this clinical trial is intended
for use by clinical oncologists in carefully structured settings, and
may not prove to be more effective than standard treatment. A responsible
investigator associated with this clinical trial should be consulted
before using this protocol.
O'Rourke N, Paul J, Hill J: Radiotherapy to mesothelioma drain sites
may not be worthwhile: interim report of a randomized study. Lung Cancer
29(suppl 2): 168, 2000
Trial Contact Information
Trial Lead Organizations
Cancer Research UK Clinical Trials Unit at the University of
Noelle O'Rourke, MD, Protocol chair
Trial Sites and Contacts
Beatson Oncology Centre
Noelle O'Rourke, MD
Gartnavel General Hospital
Andrew Peacock, MD
Stobhill General Hospital
R Jones, MD